Evidence map›Paper›PMID 41919656›Full record

ArticleInternational journal of rheumatic diseases2026

Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non-Biologic Treatment: Results From an Overlap Weighting Analysis in High-Risk Patients With Axial Spondyloarthritis.

Nigil Haroon, Zeynep Baskurt, Tina Chim, Robert D Inman, Thomas Kumke, Rachel Tham, Mindy Kim, Irene van der Horst-Bruinsma, Lianne S Gensler

Registry-linked trialAbstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of rheumatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03020992 (Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03020992 phase4completednot on this map

Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)

TypeinterventionalSponsorUCB Biopharma SRLRan2016 to 2020Enrolled89ConditionsAxial Spondyloarthritis (axSpA), Anterior Uveitis (AU)ArmsCertolizumab Pegol
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nigil HaroonDepartment of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0003-3210-4771
Zeynep BaskurtDepartment of Biostatistics, University Health Network, Toronto, Ontario, Canada.
Tina ChimDepartment of Rheumatology, University Health Network, Schroeder Arthritis Institute, Toronto, Ontario, Canada.
Robert D InmanDepartment of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, Ontario, Canada.
Thomas KumkeUCB, Monheim am Rhein, Germany.
Rachel ThamUCB, Slough, UK.
Mindy KimUCB, Atlanta, Georgia, USA.
Irene van der Horst-BruinsmaDepartment of Rheumatology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Lianne S GenslerDepartment of Medicine/Rheumatology, University of California San Francisco, San Francisco, California, USA.

Funding

UCB
6 · The paper itself

Abstract

objectiveAcute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation of axial spondyloarthritis (axSpA). This study compared the effect of the tumor necrosis factor inhibitor (TNFi) certolizumab pegol (CZP) with standard non-biologic care, on AAU flare rate in patients with axSpA and high risk of recurrent uveitis flares.

methodsC-VIEW (NCT03020992) was an open-label, multicenter study in which patients with radiographic or non-radiographic axSpA and high risk of uveitis flares received CZP for 96 weeks. Here, AAU flare rate was compared between patients in C-VIEW (up to 120 weeks) and high-risk patients with axSpA receiving standard non-biologic treatment from the University of California, San Francisco (UCSF) and University Health Network Toronto Western Hospital (UHN). Overlap weighting (OW) was utilized to adjust for potential confounders, followed by Poisson regression to evaluate the effect of CZP on AAU flare rate.

resultsEighty-seven patients from C-VIEW were compared to 75 axSpA patients with comparative disease activity and not on biologic treatment (UCSF n = 40; UHN n = 35). After OW, there were no significant differences between groups in baseline characteristics included in the model. The AAU flare rate was significantly lower for patients treated with CZP than in the comparator population: after OW, a 70.9% lower AAU flare rate was associated with CZP treatment (risk ratio [95% confidence interval]: 0.29 [0.18, 0.47]; p < 0.001).

conclusionThis study supports the findings of C-VIEW and demonstrates the benefit of CZP over standard non-biologic treatment as a promising therapeutic option in reducing AAU flares among high-risk patients with axSpA.

Indexed as

Axial SpondyloarthritisCertolizumab PegolUveitis, AnteriorAdultFemaleHumansMaleMiddle AgedRecurrenceRisk FactorsTime FactorsTreatment OutcomeCertolizumab Pegolacute anterior uveitisaxial SpondyloarthritisCertolizumab Pegolpropensity score weighting

Identifiers

PMID41919656
PMCPMC13041185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.